This report describes and explains the chronic lower back pain market and covers 2019-2024, termed the historic period, and 2024-2029, 2034F termed the forecast period. The report evaluates the market across each region and for the major economies within each region.
The global chronic lower back pain market reached a value of nearly $7.72 billion in 2024, having grown at a compound annual growth rate (CAGR) of 2.60% since 2019. The market is expected to grow from $7.72 billion in 2024 to $9.7 billion in 2029 at a rate of 4.67%. The market is then expected to grow at a CAGR of 4.36% from 2029 and reach $12.01 billion in 2034.
Growth in the historic period resulted from the favorable government initiatives, growing awareness about pain management and strong economic growth in emerging markets. Factors that negatively affected growth in the historic period were low health access in developing countries.
Going forward, increasing healthcare expenditure, rising aging population, rising prevalence of chronic diseases and increasing healthcare access in emerging markets will drive the growth. Factor that could hinder the growth of the chronic lower back pain market in the future include limited availability of skilled professionals.
The global chronic lower back pain market is concentrated, with large players operating in the market. The top ten competitors in the market made up to 42.25% of the total market in 2023. Johnson & Johnson Services Inc. was the largest competitor with a 8.08% share of the market, followed by Pfizer Inc. with 5.81%, Novartis AG. with 5.62%, Medtronic plc. with 5.32%, Eli Lilly and Company. With 5.27%, Hisamitsu Pharmaceutical Co. Inc. with 2.60%, Boehringer Ingelheim GmbH. with 2.55%, AstraZeneca plc. with 2.47%, Endo International plc with 2.27% and AbbVie Inc. with 2.24%.
North America was the largest region in the chronic lower back pain market, accounting for 40.57% or $3.13 billion of the total in 2024. It was followed by Asia Pacific, Western Europe and then the other regions. Going forward, the fastest-growing regions in the chronic lower back pain market will be Asia Pacific and South America where growth will be at CAGRs of 5.71% and 5.40% respectively. These will be followed by Africa and Middle East where the markets are expected to grow at CAGRs of 4.98% and 4.81% respectively.
The chronic lower back pain market is segmented by type of pain into diskogenic pain, lumbar spinal stenosis, sacroiliac pain, facet-joint pain, radicular pain, muscular pain and other types of pain. The diskogenic pain market was the largest segment of the chronic lower back pain market segmented by type of pain, accounting for 32.56% or $2.51 billion of the total in 2024. Going forward, the radicular pain segment is expected to be the fastest growing segment in the chronic lower back pain market segmented by type of pain, at a CAGR of 5.66% during 2024-2029.
The chronic lower back pain market is segmented by diagnosis into clinical history, physical examination, imaging guidelines and assessment of pain. The clinical history market was the largest segment of the chronic lower back pain market segmented by diagnosis, accounting for 33.68% or $2.6 billion of the total in 2024. Going forward, the imaging guidelines segment is expected to be the fastest growing segment in the chronic lower back pain market segmented by diagnosis, at a CAGR of 6.89% during 2024-2029.
The chronic lower back pain market is segmented by end-user into hospitals, orthopedic clinics, ambulatory surgery centers and other end-users. The hospitals market was the largest segment of the chronic lower back pain market segmented by end-user, accounting for 44.65% or $3.44 billion of the total in 2024. Going forward, the ambulatory surgery centers segment is expected to be the fastest growing segment in the payments market segmented by end-user, at a CAGR of 6.54% during 2024-2029.
The top opportunities in the chronic lower back pain market segmented by type of pain will arise in the diskogenic pain segment, which will gain $676.24 million of global annual sales by 2029. The top opportunities in the chronic lower back pain market segmented by diagnosis will arise in the imaging guidelines segment, which will gain $869.6 million of global annual sales by 2029. The top opportunities in the chronic lower back pain market segmented by end-user will arise in the hospitals segment, which will gain $788.5 million of global annual sales by 2029. The chronic lower back pain market size will gain the most in USA at $625.79 million.
Market-trend-based strategies for the chronic lower back pain market include innovative spinal cord stimulation approved for non-surgical back and leg pain, artificial intelligence (AI)- infused spinal cord stimulation, developing products with advanced technologies such as BurstDR SCS technology, personalized back pain solutions powered by artificial intelligence (AI) and medical insights, development of advanced treatment facilities to provide comprehensive care for managing pain stemming and cutting-edge TGF-β modulation therapy.
Player-adopted strategies in the chronic lower back pain market include focus on strengthening their business expertise through new drug launches, focus on expanding its business operations through partnerships and renewals and focus on expanding its business through new product approvals.
To take advantage of the opportunities, the analyst recommends the chronic lower back pain companies to focus on advancing non-surgical pain management solutions, focus on Ai-infused spinal cord stimulation, focus on developing advanced pain management technologies, focus on personalized Ai-powered solutions, focus on expanding advanced treatment facilities, focus on radicular pain to drive growth, expand in emerging markets, continue to focus on developed markets, focus on expanding strategic distribution partnerships, focus on value-based pricing for chronic lower back pain solutions, focus on targeted digital campaigns, focus on partnerships with healthcare providers and focus on targeted strategies for orthopedic clinics.
The global chronic lower back pain market reached a value of nearly $7.72 billion in 2024, having grown at a compound annual growth rate (CAGR) of 2.60% since 2019. The market is expected to grow from $7.72 billion in 2024 to $9.7 billion in 2029 at a rate of 4.67%. The market is then expected to grow at a CAGR of 4.36% from 2029 and reach $12.01 billion in 2034.
Growth in the historic period resulted from the favorable government initiatives, growing awareness about pain management and strong economic growth in emerging markets. Factors that negatively affected growth in the historic period were low health access in developing countries.
Going forward, increasing healthcare expenditure, rising aging population, rising prevalence of chronic diseases and increasing healthcare access in emerging markets will drive the growth. Factor that could hinder the growth of the chronic lower back pain market in the future include limited availability of skilled professionals.
The global chronic lower back pain market is concentrated, with large players operating in the market. The top ten competitors in the market made up to 42.25% of the total market in 2023. Johnson & Johnson Services Inc. was the largest competitor with a 8.08% share of the market, followed by Pfizer Inc. with 5.81%, Novartis AG. with 5.62%, Medtronic plc. with 5.32%, Eli Lilly and Company. With 5.27%, Hisamitsu Pharmaceutical Co. Inc. with 2.60%, Boehringer Ingelheim GmbH. with 2.55%, AstraZeneca plc. with 2.47%, Endo International plc with 2.27% and AbbVie Inc. with 2.24%.
North America was the largest region in the chronic lower back pain market, accounting for 40.57% or $3.13 billion of the total in 2024. It was followed by Asia Pacific, Western Europe and then the other regions. Going forward, the fastest-growing regions in the chronic lower back pain market will be Asia Pacific and South America where growth will be at CAGRs of 5.71% and 5.40% respectively. These will be followed by Africa and Middle East where the markets are expected to grow at CAGRs of 4.98% and 4.81% respectively.
The chronic lower back pain market is segmented by type of pain into diskogenic pain, lumbar spinal stenosis, sacroiliac pain, facet-joint pain, radicular pain, muscular pain and other types of pain. The diskogenic pain market was the largest segment of the chronic lower back pain market segmented by type of pain, accounting for 32.56% or $2.51 billion of the total in 2024. Going forward, the radicular pain segment is expected to be the fastest growing segment in the chronic lower back pain market segmented by type of pain, at a CAGR of 5.66% during 2024-2029.
The chronic lower back pain market is segmented by diagnosis into clinical history, physical examination, imaging guidelines and assessment of pain. The clinical history market was the largest segment of the chronic lower back pain market segmented by diagnosis, accounting for 33.68% or $2.6 billion of the total in 2024. Going forward, the imaging guidelines segment is expected to be the fastest growing segment in the chronic lower back pain market segmented by diagnosis, at a CAGR of 6.89% during 2024-2029.
The chronic lower back pain market is segmented by end-user into hospitals, orthopedic clinics, ambulatory surgery centers and other end-users. The hospitals market was the largest segment of the chronic lower back pain market segmented by end-user, accounting for 44.65% or $3.44 billion of the total in 2024. Going forward, the ambulatory surgery centers segment is expected to be the fastest growing segment in the payments market segmented by end-user, at a CAGR of 6.54% during 2024-2029.
The top opportunities in the chronic lower back pain market segmented by type of pain will arise in the diskogenic pain segment, which will gain $676.24 million of global annual sales by 2029. The top opportunities in the chronic lower back pain market segmented by diagnosis will arise in the imaging guidelines segment, which will gain $869.6 million of global annual sales by 2029. The top opportunities in the chronic lower back pain market segmented by end-user will arise in the hospitals segment, which will gain $788.5 million of global annual sales by 2029. The chronic lower back pain market size will gain the most in USA at $625.79 million.
Market-trend-based strategies for the chronic lower back pain market include innovative spinal cord stimulation approved for non-surgical back and leg pain, artificial intelligence (AI)- infused spinal cord stimulation, developing products with advanced technologies such as BurstDR SCS technology, personalized back pain solutions powered by artificial intelligence (AI) and medical insights, development of advanced treatment facilities to provide comprehensive care for managing pain stemming and cutting-edge TGF-β modulation therapy.
Player-adopted strategies in the chronic lower back pain market include focus on strengthening their business expertise through new drug launches, focus on expanding its business operations through partnerships and renewals and focus on expanding its business through new product approvals.
To take advantage of the opportunities, the analyst recommends the chronic lower back pain companies to focus on advancing non-surgical pain management solutions, focus on Ai-infused spinal cord stimulation, focus on developing advanced pain management technologies, focus on personalized Ai-powered solutions, focus on expanding advanced treatment facilities, focus on radicular pain to drive growth, expand in emerging markets, continue to focus on developed markets, focus on expanding strategic distribution partnerships, focus on value-based pricing for chronic lower back pain solutions, focus on targeted digital campaigns, focus on partnerships with healthcare providers and focus on targeted strategies for orthopedic clinics.
Major Market Trends
- Innovative Spinal Cord Stimulation Approved For Non-Surgical Back and Leg Pain
- AI-Infused Spinal Cord Stimulation Redefines Pain Therapy
- Revolutionizing Chronic Back Pain Treatment With Spinal Cord Stimulation Technology
- Personalized Back Pain Solutions Powered by AI and Medical Insights
- Advanced Treatment Facility For Managing Chronic Pain From Various Causes
- Cutting-Edge TGF-Β Modulation Therapy Progresses in Clinical Trials
Key Mergers and Acquisitions
- Boston Scientific Acquired Relievant Medsystems To Expand Chronic Pain Management Portfolio
- Stryker Corporation Acquired Vertos Medical To Enhance Minimally Invasive Pain Management Portfolio
- Nevro Corp Acquired Vyrsa Technologies For Expanding Chronic Pain Treatment Solutions
- Silony Medical International AG Acquired Centinel Fusion Portfolio To Improve Treatment Options
Table of Contents
1 Executive Summary
6 Market Characteristics
7 Major Market Trends
8 Chronic Lower Back Pain Market - Macro Economic Scenario
9 Global Market Size Global Market Size and Growth
10 Global Chronic Lower Back Pain Market Segmentation
11 Chronic Lower Back Pain Market, Regional and Country Analysis
12 Asia-Pacific Market
13 Western Europe Market
14 Eastern Europe Market
15 North America Market
16 South America Market
17 Middle East Market
18 Africa Market
19 Competitive Landscape and Company Profiles
20 Other Major and Innovative Companies
23 Key Mergers and Acquisitions
24 Opportunities and Strategies
25 Chronic Lower Back Pain Market, Conclusions and Recommendations
26 Appendix
Executive Summary
Chronic Lower Back Pain Global Market Opportunities And Strategies To 2034 provides the strategists; marketers and senior management with the critical information they need to assess the global chronic lower back pain market as it emerges from the COVID-19 shut down.Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market research findings.
- Benchmark performance against key competitors.
- Utilize the relationships between key data sets for superior strategizing.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis.
Description
Where is the largest and fastest-growing market for chronic lower back pain? How does the market relate to the overall economy; demography and other similar markets? What forces will shape the market going forward? The chronic lower back pain market global report answers all these questions and many more.The report covers market characteristics; size and growth; segmentation; regional and country breakdowns; competitive landscape; market shares; trends and strategies for this market. It traces the market’s history and forecasts market growth by geography. It places the market within the context of the wider chronic lower back pain market; and compares it with other markets.
The report covers the following chapters
- Introduction and Market Characteristics - Brief introduction to the segmentations covered in the market, definitions and explanations about the segment by type of pain, by diagnosis and by end-user.
- Key Trends - Highlights the major trends shaping the global market. This section also highlights likely future developments in the market.
- Macro-Economic Scenario - The report provides an analysis of the impact of the COVID-19 pandemic, impact of the Russia-Ukraine war and impact of rising inflation on global and regional markets, providing strategic insights for businesses in the chronic lower back pain market.
- Global Market Size And Growth - Global historic (2019-2024) and forecast (2024-2029, 2034F) market values and drivers and restraints that support and control the growth of the market in the historic and forecast periods.
- Regional And Country Analysis - Historic (2019-2024) and forecast (2024-2029, 2034F) market values and growth and market share comparison by region and country.
- Market Segmentation - Contains the market values (2019-2024) (2024-2029, 2034F) and analysis for each segment by type of pain, by diagnosis and by end-user in the market. Historic (2019-2024) and forecast (2024-2029) and (2029-2034) market values and growth and market share comparison by region market.
- Regional Market Size and Growth - Regional market size (2024), historic (2019-2024) and forecast (2024-2029, 2034F) market values and growth and market share comparison of countries within the region. This report includes information on all the regions Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa and major countries within each region.
- Competitive Landscape - Details on the competitive landscape of the market, estimated market shares and company profiles of the leading players.
- Other Major And Innovative Companies - Details on the company profiles of other major and innovative companies in the market.
- Competitive Benchmarking - Briefs on the financials comparison between major players in the market.
- Competitive Dashboard - Briefs on competitive dashboard of major players.
- Key Mergers and Acquisitions - Information on recent mergers and acquisitions in the market is covered in the report. This section gives key financial details of mergers and acquisitions which have shaped the market in recent years.
- Market Opportunities And Strategies - Describes market opportunities and strategies based on findings of the research, with information on growth opportunities across countries, segments and strategies to be followed in those markets.
- Conclusions And Recommendations - This section includes recommendations for chronic lower back pain providers in terms of product/service offerings geographic expansion, marketing strategies and target groups.
- Appendix - This section includes details on the NAICS codes covered, abbreviations and currencies codes used in this report.
Markets Covered:
1) By Type Of Pain: Diskogenic Pain; Lumbar Spinal Stenosis; Sacroiliac Pain; Facet-Joint Pain; Radicular Pain; Muscular Pain; Other Types Of Pain2) By Diagnosis: Clinical History; Physical Examination; Imaging Guidelines; Assessment Of Pain
3) By End-User: Hospitals; Orthopedic Clinics; Ambulatory Surgery Centers; Other End-Users
Key Companies Mentioned: Johnson & Johnson Services Inc.; Pfizer Inc.; Novartis AG; Medtronic plc; Eli Lilly and Company; Hisamitsu Pharmaceutical Co. Inc.
Countries: China; Australia; India; Indonesia; Japan; South Korea; USA; Canada; Brazil; France; Germany; UK; Italy; Spain; Russia
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets; GDP proportions; expenditure per capita; chronic lower back pain indicators comparison.
Data Segmentation: Country and regional historic and forecast data; market share of competitors; market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Companies Mentioned
The major companies featured in this Chronic Lower Back Pain market report include:- Johnson & Johnson Services Inc.
- Pfizer Inc.
- Novartis AG
- Medtronic plc
- Eli Lilly and Company
- Hisamitsu Pharmaceutical Co. Inc.
- Hisamitsu Pharmaceutical Co. Inc.
- Boehringer Ingelheim GmbH
- AstraZeneca plc
- Endo International plc
- AbbVie Inc.
- Hoogland Spine Products (HSP) GmbH
- Huaxiang Group
- Neurabody
- NEC Corporation
- King Edward Memorial (KEM) Hospital
- Mesoblast Limited
- Dr. Reddy’s Laboratories Ltd
- Kyowa Kirin Co., Ltd
- Argenx
- Axis Spine Technologies
- Persica Pharmaceuticals
- Ipsen Pharma
- Bayer HealthCare
- Biotronik
- Velocity Clinical
- Menarini Group
- Almirall
- Grünenthal
- Sanofi S.A
- Endo
- Koninklijke Philips N.V
- Abbott Laboratories
- Trinity Biotech plc
- EKF Diagnostics
- A. Menarini Diagnostics Ltd
- Roche Diagnostics
- Bio-Rad Laboratories
- Pain BC
- DiscGenics
- Boston Scientific Corporation
- BioWave Corporation
- Persica Pharmaceuticals
- Zimmer Biomet Holdings Inc
- AppliedVR
- Relievant Medsystems Inc
- Nevro Corp
- Vyrsa Technologies
- Neuronoff
- Creative Medical Technology Holdings, Inc
- NRX Pharmaceuticals Inc
- Stryker Corporation
- Vertos Medical Inc
- Pacira Biosciences Inc
- Aspen Medical Products
- SpineGuard
- EMS S/A
- ZygoFix
- Medoc Ltd
- BrainsWay Ltd
- Sandoz Group AG
- Southern Medical (Pty) Ltd
- SASpine
- EliteSurgical
- TiTaMED
- iSpine
- GE Healthcare
Table Information
Report Attribute | Details |
---|---|
No. of Pages | 316 |
Published | March 2025 |
Forecast Period | 2024 - 2034 |
Estimated Market Value ( USD | $ 7.72 Billion |
Forecasted Market Value ( USD | $ 12.01 Billion |
Compound Annual Growth Rate | 4.5% |
Regions Covered | Global |
No. of Companies Mentioned | 68 |